IPSEN S A/S (OTCMKTS:IPSEY) Given Average Rating of “Hold” by Analysts
IPSEN S A/S (OTCMKTS:IPSEY) has earned a consensus recommendation of “Hold” from the seven brokerages that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company.
Several brokerages have commented on IPSEY. Barclays reiterated an “equal weight” rating on shares of IPSEN S A/S in a research report on Monday, April 20th. Credit Suisse Group upgraded shares of IPSEN S A/S from an “underperform” rating to a “neutral” rating in a research report on Tuesday, February 11th. UBS Group reiterated a “buy” rating on shares of IPSEN S A/S in a research report on Wednesday, April 22nd. ValuEngine cut shares of IPSEN S A/S from a “hold” rating to a “sell” rating in a research report on Thursday, April 2nd. Finally, Zacks Investment Research raised IPSEN S A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd.
Shares of IPSEY opened at $17.89 on Wednesday. IPSEN S A/S has a one year low of $9.10 and a one year high of $34.30. The company has a 50-day simple moving average of $15.98 and a two-hundred day simple moving average of $19.85. The firm has a market capitalization of $6.00 billion, a PE ratio of 9.46 and a beta of 1.26.
Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.
Recommended Story: How do CD ladders protect against rising interest rates?
Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.